Dog Mast Cell Tumour Welfare | Animal Welfare Hub

Mast cell tumours (MCTs) are among the most common skin cancers in dogs; welfare-centred management balances treatment efficacy with quality of life.

Key Facts

MCTs account for approximately 20% of all skin tumours in dogs.
Boxers, Boston Terriers, Bulldogs, and Labrador Retrievers are predisposed.
Tumour grade (I, II, or III) based on histopathology predicts biological behaviour and prognosis.
Surgery is the primary treatment; wide excision margins reduce local recurrence significantly.
Targeted therapies including toceranib (Palladia) and masitinib improve outcomes in advanced disease.

Welfare Considerations

Mast cell tumours can cause local degranulation reactions — redness, swelling, and irritation around the tumour — that are uncomfortable. High-grade tumours may spread to regional lymph nodes, spleen, liver, and bone marrow, causing systemic illness. Treatment decisions require careful consideration of prognosis, treatment burden, and individual dog quality of life. Dogs on toceranib require regular monitoring and can experience gastrointestinal side effects. In cases of advanced disease, palliative care focused on comfort and dignity is an appropriate and compassionate choice.

What You Can Do

Have any new skin lump on your dog assessed by a vet promptly — never assume a lump is benign.
Discuss fine needle aspirate cytology as a first diagnostic step for skin masses.
Understand the implications of histopathology results before deciding on treatment intensity.
Use quality-of-life assessment tools regularly if your dog is undergoing cancer treatment.